Top

Published in:

01-01-2010 | Original Article

Bone metabolism after cinacalcet administration in patients with secondary hyperparathyroidism

Authors: Shozo Yano, Keiko Suzuki, Masaaki Sumi, Akihide Tokumoto, Kazushi Shigeno, Yasutoshi Himeno, Toshitsugu Sugimoto

Published in: Journal of Bone and Mineral Metabolism | Issue 1/2010

Abstract

Cinacalcet, an allosteric modulator of a calcium (Ca)-sensing receptor, significantly suppresses parathyroid hormone (PTH) secretion and bone turnover rate in chronic hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT). In this study, bone metabolism after cinacalcet treatment was examined, because hungry bone syndrome is sometimes experienced after parathyroidectomy in severe SHPT. We conducted a prospective observational study in 17 HD patients with SHPT. Cinacalcet was started at 25 mg/day, and the dose was increased step by step based on serum calcium level. A significant decrease in serum Ca and intact PTH concentration was found within 2 weeks. Tartrate-resistant acid phosphatase 5b, a good bone resorption marker, was significantly decreased at week 2 of the study. Serum bone alkaline phosphatase, a marker of bone formation, was increased at week 2 compared with the basal level. It became, however, gradually decreased until week 14. Only one patient whose bone turnover was considerably high had a mild numbness feeling. These results suggest that cinacalcet treatment might transiently accelerate bone formation with rapid suppression of bone resorption. This uncoupling could be involved in a mechanism by which cinacalcet decreases serum Ca level.

Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA et al (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516–1525CrossRefPubMed

Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW (2005) Cinaclcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 16:800–807CrossRefPubMed

Cunningham J, Danese M, Olson K, Klassen P, Chertow GM (2005) Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68:1793–1800CrossRefPubMed

Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S, KRN1493 study group (2008) Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23:328–335CrossRefPubMed

Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D, Martin D (2005) 1, 25-Dihydroxyvitamin D3 but not cincalcet HCl treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 20:1370–1377CrossRefPubMed

Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483CrossRefPubMed

Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38:938–942CrossRefPubMed

Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607–617CrossRefPubMed

Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK (2001) Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131–2138PubMed

10.

Yano S, Sugimoto T, Tsukamoto T, Yamaguchi T, Hattori T, Sekita KI, Kaji H, Hattori S, Kobayashi A, Chihara K (2003) Effect of parathyroidectomy on bone mineral density in hemodialysis patients with secondary hyperparathyroidism: possible usefulness of preoperative determination of parathyroid hormone level for prediction of bone regain. Horm Metab Res 35:259–264CrossRefPubMed

11.

Yokoyama K (2008) The calcium-phosphorus in guidelines for CKD-MBD. Kidney Int 74:245CrossRefPubMed

12.

Yamada S, Inaba M, Kurajoh M, Shidara K, Imanishi Y, Ishimura E, Nishizawa Y (2008) Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin Endocrinol 69:189–196CrossRef

13.

Chu P, Chao TY, Lin YF, Janckila AJ, Yam LT (2003) Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis 41:1052–1059CrossRefPubMed

14.

Ohashi T, Igarashi Y, Mochizuki Y, Miura T, Inaba N, Katayama K, Tomonaga T, Nomura F (2007) Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b. Clin Chim Acta 376:205–212CrossRefPubMed

15.

National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1–S201

16.

Shigematsu T, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S (2008) Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism. Am J Nephrol 29:230–236CrossRefPubMed

17.

Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF (1998) Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95:4040–4045CrossRefPubMed

18.

Brown EM, MacLeod RJ (2001) Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81:239–297PubMed

19.

Yano S, Brown EM (2005) Calcium-sensing receptor. In: Naveh-Many T (ed) Molecular biology of the parathyroid. Landes Bioscience/Eurekah.com and Kluwer Academic/Plenum, New York, pp 44–56CrossRef

20.

Silverberg SJ, Bone HGIII, Marriott TB, Locker FG, Thys-Jacobs S, Dziem G, Kaatz S, Sanguinetti EL, Bilezikian JP (1997) Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 337:1506–1510CrossRefPubMed

21.

Yamaguchi T (2008) The calcium-sensing receptor in bone. J Bone Miner Metab 26:301–311CrossRefPubMed

22.

Chattopadhyay N, Yano S, Tfelt-Hansen J, Rooney P, Kanuparthi D, Bandyopadhyay S, Ren X, Terwilliger E, Brown EM (2004) Mitogenic action of calcium-sensing receptor on rat calvarial osteoblasts. Endocrinology 145:3451–3462CrossRefPubMed

23.

Dvorak MM, Siddiqua A, Ward DT, Carter DH, Dallas SL, Nemeth EF, Riccardi D (2004) Physiological changes in extracellular calcium concentration directly control osteoblast function in the absence of calciotropic hormones. Proc Natl Acad Sci USA 101:5140–5145CrossRefPubMed

24.

Yamauchi M, Yamaguchi T, Kaji H, Sugimoto T, Chihara K (2005) Involvement of calcium-sensing receptor in osteoblastic differentiation of of mouse MC3T3–E1 cells. Am J Physiol Endocrinol Metab 288:E608–E616CrossRefPubMed

25.

Kameda T, Mano H, Yamada Y, Takai H, Amizuka N, Kobori M, Izumi N, Kawashima H, Ozawa H, Ikeda K, Kameda A, Hakeda Y, Kumegawa M (1998) Calcium-sensing receptor in mature osteoclasts, which are bone resorbing cells. Biochem Biophys Res Commun 245:419–422CrossRefPubMed

26.

Kanatani M, Sugimoto T, Kanzawa M, Yano S, Chihara K (1999) High extracellular calcium inhibits osteoclast-like cell formation by directly acting on the calcium-sensing receptor existing in osteoclast precursor cells. Biochem Biophys Res Commun 261:144–148CrossRefPubMed

27.

Mentaverri R, Yano S, Chattopadhyay N, Petit L, Kifor O, Kamel S, Terwilliger EF, Brazier M, Brown EM (2006) The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis. FASEB J 20:2562–2564CrossRefPubMed

28.

Yajima A, Inaba M, Ogawa Y, Tominaga Y, Tanizawa T, Inou T, Otsubo O (2007) Significance of time-course changes of serum bone markers after parathyroidectomy in patients with uraemic hyperparathyroidism. Nephrol Dial Transplant 22:1645–1657CrossRefPubMed

29.

Lazar ES, Stankus N (2007) Cinacalcet-induced hungry bone syndrome. Semin Dial 20:83–85CrossRefPubMed

30.

Yajima A, Akizawa T, Tsukamoto Y, Kurihara S, Ito A, K Study Group (2008) Impact of Cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism. Ther Apher Dial 12:S38–S43CrossRefPubMed

31.

Rodriguez ME, Almaden Y, Cañadillas S, Canalejo A, Siendones E, Lopez I, Aguilera-Tejero E, Martin D, Rodriguez M (2007) The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Physiol Renal Physiol 292:F1390–F1395CrossRefPubMed

32.

Shiizaki K, Negi S, Hatamura I, Sakaguchi T, Saji F, Kunimoto K, Mizobuchi M, Imazeki I, Ooshima A, Akizawa T (2005) Biochemical and cellular effects of direct maxacalcitol injection into parathyroid gland in uremic rats. J Am Soc Nephrol 16:97–108CrossRefPubMed

33.

Carrillo-López N, Alvarez-Hernández D, González-Suárez I, Román-García P, Valdivielso JM, Fernández-Martín JL, Cannata-Andía JB (2008) Simultaneous changes in the calcium-sensing receptor and the vitamin D receptor under the influence of calcium and calcitriol. Nephrol Dial Transplant 23:3479–3484CrossRefPubMed

34.

Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, Bushinsky DA, TARGET Investigators (2008) Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 23:2311–2318CrossRefPubMed

Title: Bone metabolism after cinacalcet administration in patients with secondary hyperparathyroidism
Authors: Shozo Yano
Keiko Suzuki
Masaaki Sumi
Akihide Tokumoto
Kazushi Shigeno
Yasutoshi Himeno
Toshitsugu Sugimoto
Publication date: 01-01-2010
Publisher: Springer Japan
Published in: Journal of Bone and Mineral Metabolism / Issue 1/2010
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-009-0102-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Validation of the Japanese Osteoporosis Quality of Life Questionnaire

High weight or body mass index increase the risk of vertebral fractures in postmenopausal osteoporotic women

Prostaglandin expression profile in hypoxic osteoblastic cells

Relationships between falls, spinal curvature, spinal mobility and back extensor strength in elderly people

The effect of thiazolidinediones on bone mineral density in Chinese older patients with type 2 diabetes

The effects of recombinant human TSH on bone turnover in patients after thyroidectomy

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials